Wockhardt activates Zaynich push, eyes global licensing deals

Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing deals while preparing for potential solo commercialization in key markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AQmcYDl
via IFTTT